Differential effect of 3-hydroxy-3-methylglutarylcoenzyme a reductase inhibitors on plasma paraoxonase 1 activity in the rat

Polish Journal of Pharmacology

Volumn 54, Issue 6, 2002, Pages 661-671

  Bełtowski, Jerzy ^a   Wójcicka, Grazyna ^a   Jamroz, Anna ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Fluvastatin; Lipid peroxidation; Oxidative stress; Paraxonase; Pravastatin

Indexed keywords

ALKENE DERIVATIVE; ARYLDIALKYLPHOSPHATASE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID HYDROPEROXIDE; MALONALDEHYDE; PARAOXON; PRAVASTATIN; THIOL DERIVATIVE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; CONTROLLED STUDY; DOSE RESPONSE; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; HYDROLYSIS; LIPID PEROXIDATION; LIVER; MALE; NONHUMAN; OXIDATIVE STRESS; RAT; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL;

ADMINISTRATION, ORAL; ANIMALS; ARYLDIALKYLPHOSPHATASE; ENZYME ACTIVATION; ESTERASES; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; RATS; RATS, WISTAR;

EID: 0036968207     PISSN: 12306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Arnaiz S.L., Travacio M., Monserrat A.J., Cutrin J.C., Llesuy S., Boveris A.: Hydrogen peroxide metabolism during peroxisome proliferation by fenofibrate. Biochim. Biophys. Acta, 1995, 1272, 175-180.
2. Arnaiz S.L., Travacio M., Monserrat A.J., Cutrin J.C., Llesuy S., Boveris A.: Chemiluminescence and antioxidant levels during peroxisome proliferation by fenofibrate. Biochim. Biophys. Acta, 1997, 1360, 222-228.
3. Aviram M., Billecke S., Sorenson R., Bisgaier C., Newton R., Rosenblat M., Erogul J., Hsu C., Dunlop C., La Du B.: Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. Arterioscler. Thromb. Vasc. Biol., 1998, 18, 1617-1624.
4. Aviram M., Rosenblat M., Billecke S., Erogul J., Sorenson R., Bisgaier C.L., Newton R.S., La Du B.: Human serum paraoxonase (PON1) is inactivated by oxidized low density lipoproteins and preserved by antioxidants. Free Radical Biol. Med., 1999, 26, 892-904.
5. Ayub A., Mackness M.I., Arrol S., Mackness B., Patel J., Durrington P.M.: Serum paraoxonase after myocardial infarction. Arterioscler. Thromb. Vasc. Biol., 1999, 19, 330-335.
6. Bełtowski J., Wójcicka G., Mydlarczyk M., Jamroz A.: Cerivastatin modulates plasma paraoxonase/arylesterase activity and oxidant-antioxidant balance in the rat. Pol. J. Pharmacol., 2002, 54, 143-150.
7. Benzie I.F.F., Strain J.J.: The ferric reducing ability of plasma (FRAP) as a measure of "antioxidant power": The FRAP assay. Anal. Biochem., 1996, 239, 70-76.
8. Berthou L., Duverger N., Emmanuel F., Langouet S., Auwerx J., Guillouzo A., Fruchart J.C., Rubin E., Denefle P., Staels B., Branellec D.: Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice. J. Clin. Invest. 1996, 97, 2408-2416.
9. Billecke S., Draganov D., Counsell R., Stetson P., Watson C., Hsu C., La Du B.N.: Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug. Metab. Dispos., 2000, 28, 1335-1342.
10. Brown B.G., Zhao X.Q., Chait A., Fisher L.D., Cheung M.C., Morse J.S., Dowdy A.A., Marino E.K., Bolson E.L., Alaupovic P., Frohlich J., Albers J.J.: Simvastatin and niacin, antioxidant vitamins, or the combination for prevention of coronary disease. N. Engl. J. Med., 2001, 345, 1583-1592.
11. Cao G., Prior R.L.: Comparison of different analytical methods for assessing total antioxidant capacity of human serum. Clin. Chem., 1998, 44, 1309-1315.
12. Cheung M.C., Zhao X.Q., Chait A., Albers J.J., Brown B.G.: Antioxidant supplements block the response of HDL to simvastatin-niacin therapy in patients with coronary artery disease and low HDL. Arterioscler. Thromb. Vasc. Biol., 2001, 21, 1320-1326.
13. Deakin S., Leviev I., Gomaraschi M., Calabresi L., Franceschini G., James R.W.: Enzymatically active paraoxonase-1 is located at the external membrane of producing cells and released by a high affinity, saturable, desorption mechanism. J. Biol. Chem., 2002, 277, 4301-4308.
14. Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., Langendorfer A., Stein E.A., Kruyer W., Gotto A.M. Jr.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA, 1998, 279, 1615-1622.
15. Draganov D.I., Stetson P.L., Watson C.E., Billecke S.S., La Du B.N.: Rabbit serum paraoxonase-3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation. J. Biol. Chem., 2000, 275, 33435-33442.
16. Durrington P.N., Mackness B., Mackness M.I.: Paraoxonase and atherosclerosis. Arterioscler. Thromb. Vasc. Biol., 2001, 21, 473-480.
17. Eckerson H.W., Ramson J., Wyte C., La Du B.N.: The human paraoxonase polymorphism: identification of phenotypes by their response to salts. Amer. J. Hum. Genet., 1983, 35, 214-227.
18. Ferre N., Camps J., Prats E., Vilella E., Paul A., Figuera L., Joven J.: Serum paraoxonase activity: a new additional test for the improved evaluation of chronic liver damage. Clin. Chem., 2002, 48, 261-268.
19. Fujioka T., Nara F., Tsujita Y, Fukushige J., Fukami M., Kuroda M.: The mechanism of lack of hypocholesterolemic effects of pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in rats. Biochim. Biophys. Acta, 1995, 1254, 7-12.
20. Hattori Y, Nakanishi N., Kasai K.: Statin enhances cytokine-mediated induction of nitric oxide synthesis in vascular smooth muscle cells. Cardiovasc. Res., 2002, 54, 649-658.
21. Inoue I., Goto S., Mizotani K., Awata T., Mastunaga T., Kawai S., Nakajima T., Hokari S., Komoda T, Katayama S.: Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: reduction of mRNA levels for interleukin-1beta, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor α (PPARα) in primary endothelial cells. Life Sci., 2000, 67, 863-876.
22. Jakubowski H.: Calcium-dependent human serum homocysteine thiolactone hydrolase. J. Biol. Chem., 2000, 275, 3957-3962.
23. James R.W., Blatter-Garin M.C., Calabresi L., Miccoli R., von Eckardstein A., Tilly-Kiesi M., Taskinen M.R., Assmann G., Franceschini G.: Modulated serum activities and concentrations of paraoxonase in high density lipoprotein deficiency states. Atherosclerosis, 1998, 139, 77-82.
24. Koh K.K.: Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc. Res., 2000, 47, 648-657.
25. Krause B.R., Newton R.S.: Lipid-lowering activity of atorvastatin and lovastatin in rodent species: triglyceride-lowering in rats correlates with efficacy in LDL animal models. Atherosclerosis, 1995, 117, 237-244.
26. Laufs U., Liao J.K.: Direct vascular effects of HMG-CoA reductase inhibitors. Trends Cardiovasc. Med., 2000, 10, 143-148.
27. Lefer A.M., Scalia R., Lefer D.J.: Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease. Cardiovasc. Res., 2001, 49, 281-287.
28. Lowry O..H., Rosebrough N.I., Farr A.L., Randall R.J.: Protein measurement with the Folin phenol reagent. J. Biol. Chem., 1951, 193, 265-275.
29. Mackness M.I., Harty D., Bhatnagar D., Winocour P.H., Arrol S., Ishola M., Durrington P.N.: Serum paraoxonase activity in familial hypercholesterolemia and insulin-dependent diabetes mellitus. Atherosclerosis, 1991, 86, 193-199.
30. Maltese W.A.: Posttranslational modification of proteins by isoprenoids in mammalian cells. FASEB J., 1990, 4, 3319-3328.
31. Martin G., Duez H., Blanquart C., Berezowski V., Poulain P., Fruchart J.C., Najib-Fruchart J., Glineur C., Staels B.: Statin-induced inhibition of the Rho-signaling pathway activates PPARα and induces HDL apo A-I. J. Clin. Invest., 2001, 107, 1423-1432.
32. Melchiorri D., Reiter R.J., Attia A.M., Hara M., Burgos A., Nistico D.: Potent protective effect of melatonin on in vivo paraquat-induced oxidative damage in rats. Life Sci., 1995, 56, 83-89.
33. Nakashima A., Ohtawa M., Iwasaki K., Wada M., Kuroda N., Nakashima K.: Inhibitory effects of fluvastatin and its metabolites on the formation of several reactive oxygen species. Life Sci., 2001, 69, 1381-1389.
34. Naurooz-Zadeh J., Tajaddini-Sarmadi J., Wolf S.P.: Measurement of plasma hydroperoxide concentrations by the ferrous oxidation-xylenol orange assay in conjuction with triphenylphosphine. Anal. Biochem., 1994, 220, 403-409.
35. Navab M., Hama-Levy S., Van Lenten B.J., Fonarow G.C., Cardinez C.J., Castellani L.W., Brennan M.L., Lusis A.J., Fogelman A.M.: Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. J. Clin. Invest., 1997, 99, 2005-2019.
36. Ng C.J., Wadleigh D.J., Gangopadhyay A., Hama S., Grijalva V., Navab M., Fogelman A.M., Reddy S.T.: Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J. Biol. Chem., 2001, 276, 44444-44449.
37. Ni W., Egashira K., Kataoka C., Kitamoto S., Koyanagi M., Inoue S., Takeshita A.: Antiinflammatory and antiarteriosclerotic actions of HMG-CoA reductase inhibitors in a rat model of chronic inhibition of nitric oxide synthesis. Circ. Res., 2001, 89, 415-421.
38. Noto H., Hashimoto Y., Satoh H., Hara M., Iso-o N., Togo M., Kimura S., Tsukamoto K.: Exclusive association of paraoxonase 1 with high-density lipoprotein particles in apolipoprotein A-I deficiency. Biochem. Biophys. Res. Commun., 2001, 289, 395-401.
39. Reddy S.T., Wadleigh D.J., Grijalva V., Ng C., Hama S., Gangopadhyay A., Shih D.M., Lusis A.J., Navab M., Fogelman A.M.: Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids. Arterioscler. Thromb. Vasc. Biol., 2001, 21, 542-547.
40. Rikitake Y., Kawashima S., Takeshita S., Yamashita T., Azumi H., Yasuhara M., Nishi H., Inoue N., Yokoyama M.: Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis, 2001, 154, 87-96.
41. Rose M.L., Rusyn I., Bojes H.K., Belyea J., Cattley R.C., Thurman R.G.: Role of Kupfer cells and oxidants in signaling peroxisome proliferator-induced hepatocyte proliferation. Mutat. Res., 2000, 448, 179-192.
42. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole, T.G., Brown L., Warnica J.W., Arnold J.M., Wun C.C., Davis B.R., Braunwald E.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N. Engl. J. Med., 1996, 335, 1001-1009.
43. Scandinavian Simvastatin Survival Study (4S): randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: Lancet, 1994, 344, 1383-1389.
44. Schiavon R., De Fanti E., Giavarina D., Biasioli S., Cavalcanto G., Guidi G.: Serum paraoxonase activity is decreased in uremic patients. Clin. Chim. Acta, 1996, 247, 71-80.
45. Sedlak J., Linosay R.H.: Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent. Anal. Biochem., 1968, 25, 192-205.
46. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W., McKillop J.H., Packard C.J.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med., 1995, 333, 1301-1307.
47. Sorenson R.C., Bisgaier C.L., Aviram M., Hsu C., Billecke S., La Du B.N.: Human serum paraoxonase/arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs; by binding phospholipids: apolipoprotein A-I stabilizes activity. Arterioscler. Thromb. Vasc. Biol., 1999, 19, 2214-2225.
48. Steiner S., Gatlin C.L., Lennon J.J., McGrath A.M., Seonarain M.D., Makusky A.J., Aponte A.M., Esquer-Blasco R., Anderson N.L.: Cholesterol biosynthesis regulation and protein changes in rat liver following treatment with fluvastatin. Toxicol. Lett., 2001, 120, 369-377.
49. Suzumura K., Ohashi N., Oka K., Yasuhara M., Narita H.: Fluvastatin depresses the enhanced lipid peroxidation in vitamin E-deficient hamsters. Free Radical Res., 2002, 35, 815-823.
50. Suzumura K., Yasuhara M., Tanak K., Suzuki T.: Protective effect of fluvastatin sodium (XU-62-320), a 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase inhibitor, on oxidative modification of human low-density lipoprotein in vitro. Biochem. Pharmacol., 1999, 57, 697-703.
51. Takemoto M., Liao J.K.: Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler. Thromb. Vasc. Biol., 2001, 21, 1712-1719.
52. Tomas M., Senti M., Garcia-Faria F., Vila J., Torrents A., Covas M., Marrugat J.: Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients. Arterioscler. Thromb. Vasc. Biol., 2000, 20, 2113-2119.
53. Tonkin A., Aylward P., Colquhoun D., Glasziou P.: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med., 1998, 339, 1349-1357.
54. Tsimihodimos V., Karabina S.A.P., Tambaki A.P., Bairaktari P., Goudevenos J.A., Chapman M.J., Elisaf M., Tselepis A.D.: Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB. Arterioscler. Thromb. Vasc. Biol., 2002, 22, 306-311.
55. Vu-Dac N., Chopin-Delannoy S., Gervois P., Bonnelye E., Martin G., Fruchart J.C., Laudet V., Staels B.: The nuclear receptors peroxisome proliferator-activated receptor α and Rev-erbα mediate the species-specific regulation of apolipoprotein A-I expression by fibrates. J. Biol. Chem., 1998, 273, 25713-25720.
56. Wassman S., Laufs U., Müller K., Konkol C., Ahlbory K., Bäumer A.T., Linz W., Böhm M., Nickenig G.: Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler. Thromb. Vasc. Biol., 2002, 22, 300-305.
57. Yamamoto A., Hoshi K., Ichihara K.: Fluvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase, scavenges free radicals and inhibits lipid peroxidation in rat liver microsomes. Eur. J. Pharmacol., 1998, 361, 143-149.